Overview

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

Status:
RECRUITING
Trial end date:
2030-12-19
Target enrollment:
Participant gender:
Summary
Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis.
Phase:
PHASE1
Details
Lead Sponsor:
Alexion Pharmaceuticals, Inc.